Actively Recruiting
Study of EIK1005 Alone and With Pembrolizumab for Advanced Solid Tumors Including MSI-H and dMMR Tumors
Led by Eikon Therapeutics · Updated on 2026-10-30
160
Participants Needed
45
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating EIK1005, a selective Werner helicase inhibitor, alone and in combination with pembrolizumab in people with advanced solid tumors, including those with Microsatellite Instability High MSI-H or Mismatch Repair Deficient dMMR tumors. This Phase 12 study aims to find the safest and most effective dose of EIK1005 and assess its safety, how the body processes it, and its initial effects. The study has two parts Part 1 includes dose escalation with EIK1005 alone Part 1A or combined with pembrolizumab Part 1B. Part 2 involves dose optimization where participants with MSI-H or dMMR tumors are randomly assigned to receive one of two selected doses of EIK1005 monotherapy. Participants without other treatment options may receive EIK1005 alone, while those with MSI-H or dMMR tumors may receive combination therapy or monotherapy depending on their group. Participants will be monitored regularly during treatment to assess side effects and how well the drugs are tolerated. Researchers will conduct scans, lab tests, and clinical evaluations to measure tumor response and control, treatment safety, and drug levels in the body. Follow-up will continue for up to two years to track outcomes such as disease progression and response duration. The total study period extends up to March 2029.
CONDITIONS
Brief Title
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Research Team
A
Ana C Mamede, PharmD
K
Krishna Kaza
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here